Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women

American Journal of Nephrology

Volumn 39, Issue 6, 2014, Pages 476-483

  Zella, Julia B ^a   Plum, Lori A ^a   Plowchalk, David R ^c   Potochoiba, Michael ^b   Clagett Dame, Margaret ^a   Deluca, Hector F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Department of Drug Metabolism Covance ^*  (United States)

^c PFIZER INC   (United States)

Author keywords

Renal failure; Secondary hyperparathyroidism; Vitamin D based therapy

Indexed keywords

2 METHYLENE 19 NOR 1ALPHA,25 DIHYDROXYVITAMIN D3; CALCITRIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; 2-METHYLENE-1,25-DIHYDROXY-19-NORVITAMIN D3; BONE DENSITY CONSERVATION AGENT; PHOSPHORUS;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SECONDARY HYPERPARATHYROIDISM; SERUM; UREMIA; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERPARATHYROIDISM, SECONDARY; METABOLISM; PHASE 1 CLINICAL TRIAL; ANIMAL MODEL; PHASE 1 CLINICAL TRIAL (TOPIC);

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORUS; POSTMENOPAUSE; RATS; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84900886470     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000362846     Document Type: Article

References (37)

1. Lumb GA, Mawer EB, Stanbury SW: The apparent vitamin D resistance of chronic renal failure. A study of the physiology of vitamin D in man. Am J Med 1971; 50: 421-441.
2. Blunt JW, DeLuca HF, Schnoes HK: 25-Hydroxycholecalciferol. A biologically active metabolite of vitamin D 3 . Biochemistry 1968; 7: 3317-3322.
3. DeLuca HF, Avioli LV: Treatment of renal osteodystrophy with 25-hydroxycholecalciferol. Arch Intern Med 1970; 126: 896-898.
4. Witmer C, Margolis A, Fontaine O, Fritsch J, Lenoir G, Broyer M, Balsan S: Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 1976; 10: 395-408.
5. Holick MF, Schnoes HK, DeLuca HF, Suda T, Cousins RJ: Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 1971; 10: 2799-2804.
6. Fraser DR, Kodicek E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 1970; 228: 764-766.
7. Gray R, Boyle I, DeLuca HF: Vitamin D metabolism: the role of kidney tissue. Science 1971; 172: 1232-1234.
8. Boyle IT, Miravet L, Gray RW, Holick MF, DeLuca HF: The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. Endocrinology 1972; 90: 605-608.
9. Holick MF, Garabedian M, DeLuca HF: 1,25-Dihydroxycholecalciferol: metabolite of vitamin D 3 active on bone in anephric rats. Science 1972; 176: 1146-1147.
10. Silverberg DS, Bettcher KB, Dossetor JB, Overton TR, Holick MF, DeLuca HF: Effect of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Can Med Assoc J 1975; 112: 190-195.
11. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry SG, Norman AW: Comparison of effects of 1α-hydroxy-vitamin D 3 and 1,25-dihydroxy-vitamin D 3 in man. J Clin Invest 1976; 57: 1540-1547.
12. Brumbaugh PF, Haussler MR: Specific binding of 1α,25- dihydroxycholecalciferol to nuclear components of chick intestine. J Biol Chem 1975; 250: 1588-1594.
13. Kream BE, Reynolds RD, Knutson JC, Eisman JA, DeLuca HF: Intestinal cytosol binders of 1,25-dihydroxyvitamin D 3 and 25-hydroxyvitamin D 3 . Arch Biochem Biophys 1976; 176: 779-787.
14. Demay MB, Kiernan MS, DeLuca HF, Kronenberg M: Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D 3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D 3 . Proc Natl Acad Sci USA 1992; 89: 8097-8101.
15. Silver J, Naveh-Many T: Vitamin D and the parathyroids; in Feldman D, Pike JW, Glorieux FH (eds): Vitamin D. Burlington/MA, Elsevier Academic Press, 1997, chapt 23, pp 537-549.
16. Slatopolsky E, Brown A, Dusso A: Calcium, phosphorus and vitamin D disorders in uremia. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 262-271.
17. Slatopolsky E, Weerts C, Theilan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143. (Pubitemid 15197358)
18. Chan JCM, Oldham SB, DeLuca HF: Effectiveness of 1α-hydroxyvitamin D in children with renal osteodystrophy associated with hemodialysis. J Pediatrics 1977; 90: 820-824. (Pubitemid 8082263)
19. Brown AJ, Ritter C, Knutson JC, Strugnell SA: The vitamin D prodrugs 1α(OH)D 2 , 1α(OH) D 3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21: 644-650. (Pubitemid 43372909)
20. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H: A new analog of calcitriol, 19-nor-1,25-(OH) 2 D 2 , suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860.
21. Finch JL, Brown AJ, Mori T, Nishii Y, Slatopolsky E: Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH) 2 D 3 . J Bone Miner Res 1992; 7: 229-233.
22. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
23. Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF: A potent analog of 1α,25-dihydroxyvitamin D 3 selectively induces bone formation. Proc Natl Acad Sci USA 2002; 99: 13487-13491. (Pubitemid 35215408)
24. DeLuca HF, Bedale W, Binkley N, Gallagher JC, Bolognese M, Peacock M, Aloia J, Clagett- Dame M, Plum L: The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo- controlled, randomized clinical trial. J Bon Miner Res 2011; 26: 538-545.
25. Potchoiba MJ, Tensfeldt TG, Nocerini MR, Silber BM: A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther 1995; 272: 953-962.
26. Potchoiba MJ, West M, Nocerini MR: Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab Dispos 1998; 26: 272-277. (Pubitemid 28182405)
27. Arbour NC, Ross TK, Zierold C, Prahl JM, DeLuca HF: A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D. Analyt Biochem 1998; 255: 148-154. (Pubitemid 28047631)
28. Wang Y, DeLuca HF: Is the vitamin D receptor found in muscle? Endocrinology 2011; 152: 354-363.
29. Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-1231. (Pubitemid 28491953)
30. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca HF: The human 25-hydroxyvitamin D 3 -24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996; 35: 8465-8472. (Pubitemid 26240500)
31. Endres B, Kato S, DeLuca HF: Metabolism of 1α,25-dihydroxyvitamin D 3 in vitamin D receptor ablated mice in vivo. Biochemistry 2000; 39: 2123-2129. (Pubitemid 30124020)
32. Frolik CA, DeLuca HF: The stimulation of 1,25-dihydroxycholecalciferol metabolism in vitamin D-deficient rats by 1,25-dihydroxycholecalciferol treatment. J Clin Invest 1973; 52: 543-548.
33. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, Mc- Cary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525. (Pubitemid 38477776)
34. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffrey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.
35. Sicinski RR, Prahl JM, Smith CM, DeLuca HF: New 1α,25-dihydroxy-19- norvitamin D 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl and 2-methylene analogs. J Med Chem 1998; 41: 4662-4674. (Pubitemid 28516465)
36. Zhu J, Barycki R, Chiellini G, DeLuca HF: Screening of selective inhibitors of 1α,25- dihydroxyvitamin D 3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli . Biochemistry 2010; 49: 10403-10411.
37. Brown AJ, Ritter CR, Finch H, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analog of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732. (Pubitemid 19228340)